Our study focuses on the 20% of the non-hereditary colon cancers with somatic MLH1 promoter methylation that are associated with a favorable prognosis and a suggested poor response to 5-fluorouracil-based regimens [11-18]. This evidence concerns the gene MLH1 and malignant colon neoplasm.